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Ischemia and Reperfusion by a
Cyclooxygenase-2–Dependent Mechanism
Andrew Liuni, BSC,* Mary Clare Luca, BSC,* Tommaso Gori, MD, PHD,† John D. Parker, MD*
Toronto, Ontario, Canada; and Mainz, Germany
Objectives The purpose of this study was to determine whether single-dose rosuvastatin (40 mg) protects against ischemia
and reperfusion (IR)–induced endothelial dysfunction in humans and whether this effect is cyclooxygenase
(COX)-2 dependent.
Background Animal studies have demonstrated that rosuvastatin can limit damage and improve recovery after IR.
Methods In a double-blind, parallel design, 20 volunteers were randomized to a single dose of oral rosuvastatin (40 mg)
or placebo. Twenty-four hours later, endothelium-dependent, flow-mediated dilation (FMD) of the radial artery
was measured before and after IR (15 min of upper arm ischemia followed by 15 min of reperfusion). In a sepa-
rate protocol, 18 volunteers received the COX-2 inhibitor celecoxib (200 mg orally twice daily) for 5 days. On day
4, subjects were randomized to single-dose rosuvastatin (40 mg) or placebo and 24 h later underwent the same
protocol as described.
Results Pre-IR FMD was similar between groups (p  NS). IR significantly blunted FMD in the placebo group (FMD pre-IR:
6.4  1.4%; FMD post-IR: 1.1  3.8%, [p  0.002]). Rosuvastatin prevented this impairment (FMD pre-IR: 7.5 
3.1%; FMD post-IR: 6.2  3.9%, [p  NS] vs. rosuvastatin pre-IR, [p  0.03] vs. placebo). Pre-treatment with
celecoxib completely abolished rosuvastatin’s protective effect (FMD pre-IR: 8.0  2.2%; FMD post-IR: 1.4 
2.0%, [p  0.001] compared with pre-IR, [p  NS] vs. placebo, [p  0.002] vs. rosuvastatin alone).
Conclusions Rosuvastatin pharmacologically prevents the development of IR-induced conduit artery endothelial dysfunc-
tion. This beneficial effect of rosuvastatin is mediated by a COX-2–dependent mechanism, evidence that
may also provide potential mechanistic insight into the reported cardiotoxic effects of COX-2 inhibitors.
(J Am Coll Cardiol 2010;55:1002–6) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.046t
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rhe goal of therapy in patients with a myocardial
nfarction is timely and effective reperfusion to the
nfarcted area. Unfortunately, reperfusion itself can con-
ribute to myocardial damage, a phenomenon called
schemia and reperfusion (IR) injury (1,2). Importantly,
ndothelial cells are particularly susceptible to and ac-
ively participate in this IR injury (3,4). Damaged and
ysfunctional endothelium reduces perfusion to areas of
revious ischemia and can exacerbate tissue injury, con-
rom the *Division of Cardiology, Mount Sinai and University Health Network
ospitals and Department of Pharmacology and Toxicology, University of Toronto,
oronto, Ontario, Canada; and the †Department of Cardiology, University of Mainz,
ainz, Germany. This study was funded by a grant from the Heart and Stroke
oundation of Canada. Dr. Parker holds a Career Investigator Award from the Heart
nd Stroke Foundation of Ontario, Toronto, Ontario, Canada.a
Manuscript received July 13, 2009; revised manuscript received October 21, 2009,
ccepted November 2, 2009.ributing to subsequent organ damage (5). Thus, the
ndothelium is a major determinant of the capacity of
issue to recover from IR, and interventions capable of
rotecting the endothelium from IR should be considered
f direct clinical interest.
Exposure to brief periods of ischemia (ischemic pre-
onditioning) can reduce myocardial and vascular sensi-
ivity to IR-induced injury (5,6). Importantly, studies
ave demonstrated that certain pharmacological agents
hat target important effectors of the ischemic pre-
onditioning pathway can mimic this phenotype (7,8):
gents such as sildenafil (9) and nitroglycerin (10) have
een shown to prevent IR-induced endothelial damage,
n effect termed pharmacological pre-conditioning.
-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
eductase inhibitors have also been demonstrated to have suchpreconditioning response in animal models (11–14). This
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March 9, 2010:1002–6 Endothelial Protective Effects of Rosuvastatinrotective phenotype has been shown to involve several mech-
nisms and mediators, including up-regulation of the cyclooxy-
enase (COX)-2 enzyme (15–17). Whether a similar protec-
ive phenotype occurs in humans in vivo and whether its
anifestation is COX-2 dependent remain uninvestigated.
ethods
he Mount Sinai Hospital Research Ethics Board approved
his investigator-initiated, non–industry-funded study, and all
ubjects gave informed consent. Study procedures are described
n detail in previous publications from our group (9,10).
rotocol 1: effect of rosuvastatin on IR-induced conduit
rtery endothelial dysfunction. Twenty healthy nonsmok-
ng volunteers (18 to 33 years of age) were enrolled in a
ouble-blind, randomized, placebo-controlled, parallel trial.
n the first study visit, standing blood pressure measure-
ents were obtained followed by venous blood sampling for
aseline lipid analysis. Subjects were then randomized to
eceive placebo or 40 mg rosuvastatin. Twenty-four hours
fter drug administration, standing blood pressure and
lasma lipid measurements were repeated. Subsequently,
adial artery flow-mediated dilation (FMD) was measured
s previously described (9,10,18). After this measurement
as completed, a pneumatic cuff placed above the antecu-
ital fossa was inflated to 250 mm Hg for 15 min to induce
ocal ischemia. The cuff was then deflated, and 15 min of
eperfusion were allowed before FMD was measured again.
e elected not to test endothelium-independent vasodi-
ators because previous studies already demonstrated that
his cycle of IR specifically impairs endothelium-dependent
esponses (5).
rotocol 2: effect of celecoxib pre-treatment. Eighteen
ealthy nonsmoking volunteers (18 to 33 years of age)
ere enrolled in a double-blind, randomized, placebo-
rterial Diameter and Blood Flow DataTable 1 Arterial Diameter and Blood Flow Data
Pre-IR
Radial Artery Diameter (mm) Baseline
Chang
After Wr
Protocol 1
Placebo 2.38 0.32 0
Rosuvastatin 2.29 0.25 0
Protocol 2
Celecoxib  placebo 2.43 0.20 0
Celecoxib  rosuvastatin 2.48 0.26 0
Blood Flow (ml/min) Baseline
After Wrist
Cuff Deflation
Protocol 1
Placebo 37.7 19.9 229.6 99.6
Rosuvastatin 38.2 25.8 203.5 86.7
Protocol 2
Celecoxib  placebo 46.2 19.7 221.1 40.5
Celecoxib  rosuvastatin 37.1 6.8 198.3 44.0p 0.01 versus corresponding value pre-ischemia and reperfusion (IR); †p 0.0001 versus correspond
ost-IR in the placebo group and versus both groups, protocol 2.ontrolled, parallel trial. After
onsent and baseline measure-
ents as in protocol 1, subjects
ere administered celecoxib, a
elective COX-2 inhibitor, 200
g twice daily for 5 days. On
ay 4, subjects were random-
zed to receive a single dose of
lacebo or 40 mg rosuvastatin
s in protocol 1. Twenty-four
ours after randomization, sub-
ects underwent FMD measurements before and after IR
s described previously.
tatistical analysis. Data are presented as mean  SD.
ithin-group comparisons were performed with a paired t
est. Between-group differences and the interaction of IR
nd randomization group were studied with a 2-way analysis
f variance. Post hoc comparisons were performed using the
onferroni correction. A p value of 0.05 was set as the
hreshold for significance. SAS version 9.1.3 (SAS Institute
nc., Cary, North Carolina) was used for all statistical
nalyses.
esults
ffect of rosuvastatin and celecoxib administration on
aseline parameters. There were no significant differences
n resting blood pressure, resting radial artery diameter,
aseline blood flow, reactive hyperemia, or pre-IR FMD
etween groups in either protocol (Table 1).
rotocol 1: effect of placebo and rosuvastatin adminis-
ration on IR-induced endothelial dysfunction. In both
he placebo and the rosuvastatin groups, resting radial artery
iameter and radial artery blood flow returned to baseline
alues 15 min post-IR (Table 1). Similarly, peak reactive
Post-IR
iameter
ff Deflation Baseline
Change in Diameter
After Wrist Cuff Deflation
0.03 2.43 0.33 0.02 0.10*
0.02 2.22 0.20 0.13 0.09†
0.06 2.44 0.33 0.05 0.07‡
0.05 2.50 0.26 0.03 0.05‡
active
remia (%) Baseline
After Wrist
Cuff Deflation
Reactive
Hyperemia (%)
 150 38.2 26.1 197.1 89.3 509 209
 194 36.6 22.7 216.4 81.0 571 205
 215 37.6 14.5 216.9 60.6 520 182
 99 41.7 7.8 205.9 56.8 465 181
Abbreviations
and Acronyms
COX  cyclooxygenase
FMD  flow-mediated
dilation
HMG-CoA  3-hydroxy-3-
methylglutaryl coenzyme A
IR  ischemia and
reperfusione in D
ist Cu
.15
.17
.20
.20
Re
Hype
508
548
449
460ing value pre-IR; ‡p NS versus corresponding value pre-IR, p 0.05 versus corresponding value
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Endothelial Protective Effects of Rosuvastatin March 9, 2010:1002–6yperemia was not significantly different post-IR (Table 1). IR
ignificantly blunted FMD in the placebo group (Fig. 1) (pre-IR:
.4  1.4%; post-IR: 1.1  3.8%, p  0.002). In contrast,
osuvastatin administration prevented the impairment in
MD associated with IR (Fig. 1) (pre-IR: 7.5  3.1%;
ost-IR: 6.2  3.9%, [p  NS] vs. FMD pre-IR, [p 
.002] vs. placebo, [p  0.03] for the interaction of IR and
roup).
rotocol 2: effect of celecoxib pre-treatment on
osuvastatin-mediated protection. As in protocol 1, resting
rterial diameter, radial artery blood flow, and peak reactive
yperemia were not modified by IR in the celecoxib placebo
nd the celecoxib  rosuvastatin groups (Table 1). IR signif-
cantly blunted FMD responses in the subjects who received
elecoxib placebo (Fig. 2) (pre-IR: 8.1  1.9%; post-IR:
.2  2.8%, p  0.001). Similarly, in the subjects who
eceived celecoxib  rosuvastatin, IR blunted FMD to values
imilar to those observed in the placebo group of protocol 1
Fig. 2) (pre-IR: 8.0  2.2%; post-IR: 1.4  2.0%, [p 
.001] vs. FMD pre-IR, [p  NS] vs. celecoxib  placebo
roup, [p  0.04] for overall group effect, [p  0.004] for the
nteraction of IR and group, [p 0.002] vs. rosuvastatin group
n protocol 1).
ffect of rosuvastatin and celecoxib administration on
ipid parameters. There were no significant differences in
otal cholesterol, high-density lipoprotein, low-density li-
oprotein, or triglycerides between groups nor was there a
ignificant difference in lipid parameters after the 24-hour
eriod of treatment with rosuvastatin, celecoxib, or placebo
n either protocol (Table 2).
iscussion
he present study demonstrates, for the first time in
umans, the ability of the HMG-CoA reductase inhib-
Figure 1 FMD Before and After IR in
Placebo and Rosuvastatin Groups
Flow-mediated dilation (FMD) responses pre- and post-ischemia and
reperfusion (IR). In the placebo group, FMD was significantly blunted post-
IR. This effect was prevented with rosuvastatin administration. Data are
mean  SEM. *p  0.002 versus FMD pre-IR.tor rosuvastatin to create an endothelial pharmacologicalre-conditioning effect in the setting of IR injury at the
evel of the conduit vasculature. This effect seems to be
ediated by a COX-2– dependent mechanism and is
ndependent of reductions in plasma lipids. Our results
re consistent with evidence from animal models of
schemic injury that have consistently demonstrated the
bility of HMG-CoA reductase inhibitors to decrease
nfarct size, maintain vascular function, and improve
unctional recovery after IR injury (11,12,19 –22).
We observed a significant blunting of FMD after IR in
he placebo group, whereas the administration of rosuv-
statin prevented this effect. Studies in animals suggest
hat the mechanism leading to such pre-conditioning–
imetic properties of HMG-CoA reductase inhibitors is
ikely multifactorial with up-regulation in the activity of
cto-5= nucleotidase (an enzyme responsible for the
roduction of adenosine) and of the endothelial and
nducible isoforms of nitric oxide synthase believed to
lay a role (16,20,23). In addition, specific importance
as been given to the induction of COX-2 activity, which
s believed to depend on a HMG-CoA reductase inhibi-
or–mediated increase in nitric oxide bioavailability from
oth endothelial and inducible nitric oxide synthase
ources (16,17). Our study demonstrates that the endo-
helial protection afforded by rosuvastatin is abolished in
he presence of COX-2 inhibition, suggesting that
OX-2 is at least partially involved in the signaling cascade
eading to rosuvastatin-mediated protection in humans. To
ur knowledge, the current study represents the first dem-
nstration of the importance of COX-2 in a human in vivo
re-conditioning model. This observation may have further
linical implications because it may contribute to the clari-
cation of the mechanisms behind the observed increases in
Figure 2 FMD Before and After IR in Celecoxib  Placebo
and Celecoxib  Rosuvastatin Groups
Flow-mediated dilation (FMD) responses pre- and post-ischemia and reperfusion
(IR). In both groups, FMD was significantly attenuated post-IR, demonstrating
the inhibitory action of celecoxib on rosuvastatin-mediated protection. Data are
mean  SEM. *p  0.001 versus FMD pre-IR. †p  0.002 versus rosuvasta-
tin group in protocol 1, analysis of variance results shown in text.
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March 9, 2010:1002–6 Endothelial Protective Effects of Rosuvastatinardiovascular morbidity and mortality in patients receiving
OX-2 inhibitors (24–26).
tudy limitations. The fact that the present data were
cquired in healthy volunteers and in a circulation that is
ifferent from the coronary circulation needs to be acknowl-
dged. Additionally, the assessment of IR-induced endo-
helial dysfunction was limited to the conduit circulation
nd not to the distal microcirculation, a vascular bed that
s also of importance in clinical IR injury. As mentioned
arlier, previous studies have shown the IR injury used here
pecifically impairs endothelium-dependent responses while
eaving endothelium-independent reactivity unaltered (5).
herefore, the fact that reactive hyperemia, a predominantly
ndothelium-independent process (27), is unimpaired in the
resent study should not be unexpected.
onclusions
e demonstrate that rosuvastatin administration exerts
otent endothelial protection against IR injury in conduit
essels via activation of COX-2. These results represent
he first human evidence of a direct endothelial pharma-
ological pre-conditioning effect by rosuvastatin and may
rovide a mechanistic explanation to previous observa-
ions from clinical settings (13,14). Further, our data
uggest a possible mechanistic explanation for the nega-
ive cardiovascular side effects of COX-2 inhibitors
bserved in clinical trials (24 –26).
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